By Ben Hirschler LONDON (Reuters) - AstraZeneca is accelerating its push into cancer immunotherapy, with plans to test a key experimental drug in new tumor types. The company is seen as No. 4 in a race to develop the first drug in a new class that fights cancer by unleashing the body's immune system, behind rivals Roche, Merck & Co and Bristol-Myers Squibb. AstraZeneca said on Thursday it would launch a pivotal clinical trial program with MEDI4736 in head and neck cancer this year, in addition to ongoing tests in lung cancer, and was also looking at expanding tests into other cancer types.
via Health News Headlines - Yahoo News http://ift.tt/1rLqpxM
No comments:
Post a Comment